GlassScriptPhysician profile
Iman Andalib
NPI 1144585126
$34,744.85
in general payments reported to CMS, 2019-2025
30 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $1,978 · 2021: $976 · 2022: $945 · 2023: $876 · 2024: $1,565 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,606.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27,702.63 | 2019-2025 | Exalt Model D, Wallflex Duodenal, Spyglass |
| Conmed Corporation | $1,620.08 | 2020-2024 | Conmed Dilation, Conmed Biliary, Conmed Generators |
| Ambu INC. | $763.61 | 2020-2025 | |
| Olympus America INC. | $576.71 | 2019-2024 | Hanarostent Esophagus Tts(Ccc) |
| 3-D Matrix, INC. | $572.68 | 2025 | |
| Cook Medical LLC | $555.98 | 2019-2024 | Fusion, Hemospray, Zilver Ptx |
| Steris Corporation | $497.66 | 2019-2025 | |
| Medtronic, INC. | $422.47 | 2023-2025 | Nexpowder, Prodigi, Endoflip |
| Apollo Endosurgery US INC | $384.81 | 2019-2021 | |
| Creo Medical INC. | $266.64 | 2021-2024 | Speedboat Ultraslim (Sb1l) |
| Evoendo, INC | $181.90 | 2025 | |
| Abbvie INC. | $160.02 | 2020-2024 | Rinvoq |
| Pentax of America, INC. | $153.64 | 2021-2025 | Pentax Medical, C2 Cryoballoon, Inspira |
| Laborie Medical Technologies Corp. | $126.79 | 2024 | |
| Gilead Sciences, INC. | $125.00 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $123.47 | 2022 | |
| Qol Medical, LLC | $112.72 | 2020-2023 | Sucraid |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Intercept Pharmaceuticals, INC. | $64.06 | 2022-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.38 | 2023 | Xifaxan |
| Cardinal Health 200 LLC | $32.38 | 2023 | |
| Genzyme Corporation | $29.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.43 | 2025 | Voquezna |
| Ardelyx, INC. | $22.27 | 2023 | Ibsrela |
| Micro-Tech Endoscopy USA, INC. | $20.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.99 | 2022 | |
| Amgen INC. | $18.81 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.73 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.15 | 2020 | |
| Daiichi Sankyo INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Andalib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.